Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.45 |
| ▸ | HTR1D | P28221 | 6/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10599679 | 0.83 | LDHA (0.44) | HTR1AHTR1DKDM4ELDHAALDH1A1 | |
| SCHEMBL6291943 | 0.83 | ESR1 (0.59) | KDM4ELDHAALDH1A1 | |
| SCHEMBL11039123 | 0.83 | ESR1 (0.43) | KDM4ELDHAALDH1A1 | |
| SCHEMBL6296267 | 0.83 | ESR2 (0.59) | — | |
| SCHEMBL1933116 | 0.83 | ESR1 (0.40) | HTR1AHTR1DDDB1CRBNKDM4E | |
| SCHEMBL12556044 | 0.83 | ESR1 (0.40) | KDM4EALDH1A1 | |
| SCHEMBL13820745 | 0.80 | FFAR1 (0.42) | — | |
| SCHEMBL9377919 | 0.79 | MAOB (0.48) | DDB1CRBNKDM4ELDHAALDH1A1 | |
| SCHEMBL31031150 | 0.79 | HTR1A (0.40) | HTR1AHTR1DROCK2CA2 | |
| SCHEMBL31031169 | 0.79 | HTR1A (0.41) | HTR1AHTR1DCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999001453-A1 | A PROCESS FOR THE MANUFACTURE OF OPTICALLY ACTIVE CHROMANYLPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-01-14 | — | — | WO | claimed |
| EP-0025600-B1 | 2-PYRIDYL CHROMANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-12-19 | — | — | EP | claimed |
| US-6846817-B2 | Nicotine receptor ligands | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2005-01-25 | — | — | US | disclosed |
| US-20030027810-A1 | Nicotine receptor ligands | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2003-02-06 | — | — | US | disclosed |
| WO-2000073269-A2 | NICOTINE RECEPTOR LIGANDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2000-12-07 | — | — | WO | disclosed |
| WO-1999001453-A1 | A PROCESS FOR THE MANUFACTURE OF OPTICALLY ACTIVE CHROMANYLPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-01-14 | — | — | WO | disclosed |
| WO-1999001453-A1 | A PROCESS FOR THE MANUFACTURE OF OPTICALLY ACTIVE CHROMANYLPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-01-14 | — | — | WO | disclosed |
| US-4563468-A | ANTI-RHINOVIRUS 2-PYRIDYLCHROMANS | BURROUGHS WELLCOME CO. (US) | 1986-01-07 | — | — | US | disclosed |
| US-4563468-A | ANTI-RHINOVIRUS 2-PYRIDYLCHROMANS | BURROUGHS WELLCOME CO. (US) | 1986-01-07 | — | — | US | disclosed |
| EP-0025600-B1 | 2-PYRIDYL CHROMANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-12-19 | — | — | EP | disclosed |
| EP-0025600-B1 | 2-PYRIDYL CHROMANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-12-19 | — | — | EP | disclosed |
| EP-0025600-A1 | 2-Pyridyl chromans and pharmaceutical compositions containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-03-25 | — | — | EP | disclosed |
| EP-0025600-A1 | 2-Pyridyl chromans and pharmaceutical compositions containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027810-A1 | Nicotine receptor ligands | CHRNA1, CHRNB1, CHRNA9 | HTR1A 77/4885HTR1D 82/4885ROCK2 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.